Merck delivered strong third-quarter financial results that exceeded Wall Street estimates on both revenue and earnings, sparking robust buying pressure among institutional and retail investors. The company reported quarterly top-line revenue that comfortably topped consensus expectations, driven by solid demand across its pharmaceutical and animal health divisions. Adjusted earnings per share also significantly outpaced market forecasts, marking another quarter of operational outperformance and demonstrating resilient cost discipline.

The primary catalyst behind the quarterly beat was the continued strength of Merck’s flagship oncology franchise, Keytruda, along with the rapid uptake of its subcutaneous formulation. In addition, new…